All public logs
Jump to navigation
Jump to search
Combined display of all available logs of wikidoc. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).
- 10:58, 15 May 2024 Alara E. Dagsali talk contribs created page Lodoxamide (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Alomide |indicationType=treatment |indication=ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1% is indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. |adverseReactions=During clinical studies of ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1%, the most frequently reported ocular adve...")
- 23:48, 13 May 2024 Alen Antony talk contribs created page Fezolinetant (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |OTC=Yes |genericName=fezolinetant }}")
- 20:38, 13 May 2024 Muhammad Waleed talk contribs created page Talquetamab-tgvs (Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=Talquetamab-tgvs |aOrAn=a |drugClass=bispecific GPRC5D-directed CD3 T-cell engager |indicationType=treatment |indication=TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent...")
- 14:50, 13 May 2024 Alen Antony talk contribs created page Nirsevimab-alip (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=Nirsevimab-alip |aOrAn=a |drugClass=human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody |indicationType=prevention |indication=Respiratory Syncytial Virus (RSV) lower respiratory tract disease for neonates and infants born during or entering their first RSV season and children up to 24 years of age who are vulnerable to severe RSV disease in their second RSV season. |adverseReactions=rashes and injection...")
- 19:35, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1208.jpeg
- 19:35, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1208.jpeg
- 19:33, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1207.jpeg
- 19:33, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1207.jpeg
- 19:32, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1204.jpeg
- 19:32, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1204.jpeg
- 19:30, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1202.jpeg
- 19:30, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1202.jpeg
- 19:28, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1200.jpeg
- 19:28, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1200.jpeg
- 19:24, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1214.jpeg
- 19:24, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1214.jpeg
- 05:30, 12 May 2024 Kosar Doraghi talk contribs created page Somatrogon-ghla (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.con] |genericName=somatrogon-ghla |aOrAn=a |drugClass=human growth hormone analog |indicationType=treatment |indication=pediatric patients aged 3 years and older who have growth failure due to inadequate secretion of endogenous growth hormone |hasBlackBoxWarning=Yes |adverseReactions=injection site reactions, nasopharyngitis, headache, pyrexia, anemia, cough, v...")
- 05:15, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1198.jpeg
- 05:15, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1198.jpeg
- 05:13, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1215.jpeg
- 05:13, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1215.jpeg
- 20:21, 11 May 2024 Rithish Nimmagadda talk contribs created page Elfabrio (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=Pegunigalsidase Alfa-iwxj |drugClass=a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme, is a pegylated recombinant form of human α-galactosidase A |indicationType=treatment |indication=ELFABRIO is an FDA approved drug that is used for treatment of adults with confirmed Fabry disease. |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (≥15%) are infusion-associated reactio...")
- 19:36, 11 May 2024 Rithish Nimmagadda talk contribs created page Exxua (Created page with "{{DrugProjectFormSinglePage |authorTag={{ }}")
- 13:10, 9 May 2024 Rithish Nimmagadda talk contribs created page Epcoritamab-bysp (Created page with "{{DrugProjectFormSinglePage |authorTag=VSRN }}")
- 10:37, 9 May 2024 Hafiza Amna Qadeer talk contribs created page FUTIBATINIB (Created page with "{{DrugProjectFormSinglePage |authorTag=HAFIZA AMNA QADEER, MD |OTC=Yes |genericName=FUTIBATINIB |aOrAn=a |drugClass=Kinase Inhibitor |indicationType=treatment |indication=* of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. |adverseReactions=1* Nail Toxicity, stomatitis, dry skin, dry eye, alopecia 2* Musculos...")
- 04:57, 9 May 2024 Alen Antony talk contribs created page Sotagliflozin (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=sotagliflozin |aOrAn=a |drugClass=sodium-glucose co-transporter 2 (SGLT2) inhibitor |indicationType=prophylaxis |indication=heart failure in patients with risk of heart failure, type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. |adverseReactions=urinary tract infection, volume depletion, diarrhea, and hypoglycemia. }}")
- 21:32, 8 May 2024 Kosar Doraghi talk contribs created page EXXUA (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=Gepirone |aOrAn=a |drugClass=extended-release tablets |indicationType=treatment |indication=major depressive disorder (MDD) in adults |hasBlackBoxWarning=Yes |adverseReactions=dizziness, nausea, insomnia, abdominal pain, and dyspepsia |blackBoxWarningTitle=WARNING: SUICIDAL THOUGHTS AND BEHAVIORS |blackBoxWarningBody=SEE FULL PRESCRIBING INFORMATION FOR...")
- 21:27, 8 May 2024 Kosar Doraghi talk contribs created page File:IMG 1195.jpeg
- 21:27, 8 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1195.jpeg
- 21:26, 8 May 2024 Kosar Doraghi talk contribs created page File:IMG 1196.jpeg
- 21:26, 8 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1196.jpeg
- 21:19, 8 May 2024 Kosar Doraghi talk contribs created page File:IMG 1194.jpeg
- 21:19, 8 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1194.jpeg
- 17:11, 8 May 2024 Imam Ali Shah talk contribs created page File:Screenshot (245).jpg
- 17:11, 8 May 2024 Imam Ali Shah talk contribs uploaded File:Screenshot (245).jpg
- 17:02, 8 May 2024 Imam Ali Shah talk contribs created page File:RCR logo.png
- 17:02, 8 May 2024 Imam Ali Shah talk contribs uploaded File:RCR logo.png
- 16:30, 8 May 2024 Imam Ali Shah talk contribs uploaded a new version of File:Pre-contrast CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg (Pre-contrast CT scan of the abdomen and pelvis depicts an irregular nodular margin of the liver (green arrowhead), hypertrophy of the caudate lobe (orange arrow), and the presence of ascites (red arrow).)
- 16:21, 8 May 2024 Imam Ali Shah talk contribs created page File:Portal-venous phase CT scan of the abdomen and pelvis in Liver Cirrhosis.png
- 16:21, 8 May 2024 Imam Ali Shah talk contribs uploaded File:Portal-venous phase CT scan of the abdomen and pelvis in Liver Cirrhosis.png
- 16:19, 8 May 2024 Imam Ali Shah talk contribs created page File:Portal-venous phase CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg
- 16:19, 8 May 2024 Imam Ali Shah talk contribs uploaded File:Portal-venous phase CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg
- 16:18, 8 May 2024 Imam Ali Shah talk contribs created page File:Arterial phase CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg
- 16:18, 8 May 2024 Imam Ali Shah talk contribs uploaded File:Arterial phase CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg
- 16:17, 8 May 2024 Imam Ali Shah talk contribs created page File:Pre-contrast CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg
- 16:17, 8 May 2024 Imam Ali Shah talk contribs uploaded File:Pre-contrast CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg
- 14:44, 8 May 2024 Rithish Nimmagadda talk contribs created page Template:VSRN (Created page with "Rithish Nimmagadda,MBBS.[mailto:rithishnvs@gmail.com]")
- 14:20, 8 May 2024 Rithish Nimmagadda talk contribs created page User:Rithish Nimmagadda (Created page with "<nowiki> __NOTOC__ ==Your Name== ''' Rithish Nimmagadda, MBBS Research scholar <br />Contact:945-278-1660 <br /> Email: rithishnvs@gmail.com [mailto:rithishnvs@gmail.com]<br /> ==Current Position== * research scholar (list chapters here)<br /> ==Education== Medical Degree from Kamineni Academy of Medical sciences and research centre , Hyderabad , India")
- 14:10, 8 May 2024 Rithish Nimmagadda talk contribs created page FRUZAQLA (Created page with "{{DrugProjectFormSinglePage |aOrAn=a |indicationType=treatment |indication=FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. |adverseReactions=Most common adverse reactions ( are hypertension, palma...")
- 13:32, 8 May 2024 Rithish Nimmagadda talk contribs created page Fruzaqla (Created page with "{{DrugProjectFormSinglePage |authorTag=rithish }}")
- 01:53, 8 May 2024 Edzelco talk contribs created page File:LOQTORZI Dosage.png
- 01:53, 8 May 2024 Edzelco talk contribs uploaded File:LOQTORZI Dosage.png
- 17:27, 7 May 2024 Alen Antony talk contribs created page Zuranolone (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=zuranolone |aOrAn=a |drugClass=gamma-aminobutyric acid (GABA) A receptor positive modulator |indicationType=treatment |indication=postpartum depression (PPD) in adults |hasBlackBoxWarning=Yes |adverseReactions=somnolence, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection. |blackBoxWarningTitle=Impaired ability to engage in potential hazardous activity |blackBoxWarningBody=Patients are ad...")
- 22:57, 3 May 2024 Kosar Doraghi talk contribs created page Xacduro- sulbactam and durlobactam (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=sulbactam and durlobactam |aOrAn=a |drugClass=co-packaged product containing sulbactam, a beta-lactam antibacterial and beta lactamase inhibitor, and durlobactam, a beta lactamase inhibitor, |indicationType=treatment |indication=hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acin...")
- 18:20, 3 May 2024 Alen Antony talk contribs created page Perfluorhexyloctane (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |OTC=Yes |genericName=perfluorhexyloctane |aOrAn=a |drugClass=semifluorinated alkane |indicationType=treatment |indication=signs and symptoms of dry eye disease (DED). |adverseReactions=blurred vision. }}")
- 15:29, 2 May 2024 Alen Antony talk contribs created page Trofinetide (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=trofinetide }}")
- 03:29, 2 May 2024 Alen Antony talk contribs created page Zavegepant (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=zavegepant |aOrAn=a |drugClass=calcitonin gene-related peptide (CGRP) receptor antagonist. |indicationType=treatment |indication=acute migraine with or without aura in adults. |adverseReactions=taste disorders, nausea, nasal discomfort, and vomiting |fdaLIADAdult=The recommended dose is 10 mg given intranasally as a single spray in one nostril, as needed, with the maximum dosage at 10mg in 24 hours. |contraindic...")
- 21:51, 1 May 2024 Alen Antony talk contribs created page Omaveloxolone (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=omaveloxolone }}")
- 15:46, 1 May 2024 Kosar Doraghi talk contribs created page Nirsevimab (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=Nirsevimab |aOrAn=a |drugClass=respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor |indicationType=prevention |indication=RSV lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season, and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season |hasBlackBo...")
- 15:31, 1 May 2024 Kosar Doraghi talk contribs created page File:IMG 1185.jpeg
- 15:31, 1 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1185.jpeg
- 15:29, 1 May 2024 Kosar Doraghi talk contribs created page File:IMG 1187.jpeg
- 15:29, 1 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1187.jpeg
- 14:19, 1 May 2024 User account Rithish Nimmagadda talk contribs was created by Alberto Castro Molina talk contribs
- 18:57, 30 April 2024 Alara E. Dagsali talk contribs created page Isosulfan Blue (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Lymphazurin |aOrAn=a |indicationType=treatment |indication=Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therape...")
- 18:46, 30 April 2024 Alara E. Dagsali talk contribs created page Ibuprofen Lysine (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Ibuprofen lysine |aOrAn=a |indicationType=treatment |indication=Ibuprofen Lysine is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conduc...")
- 18:27, 30 April 2024 Alara E. Dagsali talk contribs created page Prussian blue (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |drugClass=RADIOGARDASE |indicationType=treatment |indication=Radiogardase is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination |adverseReactions=Most common adverse reaction (incidence >24%) was constipation Constipation was reported in 10 (24%) of 42 patients treated with R...")
- 18:14, 30 April 2024 Alara E. Dagsali talk contribs created page Botulism Antitoxin (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=BAT |aOrAn=a |indicationType=treatment |indication=BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] is a mixture of immune globulin fragments indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients. |adverseReactions=The most common adverse reactions obse...")
- 15:23, 29 April 2024 Alara E. Dagsali talk contribs created page Trastuzumab emtansine (Created page with "{{DrugProjectFormSinglePage |authorTag=AlaraE.Dagsali |genericName=ado-trastuzumab emtansine |indicationType=treatment |indication=the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. the adjuvant treatment...")
- 17:32, 26 April 2024 User account Jonathan Reyes talk contribs was created by Alberto Castro Molina talk contribs
- 22:39, 25 April 2024 Alara E. Dagsali talk contribs created page User:AED (Created page with "==Alara Ece Dagsali== '''Alara Ece Dagsali''' <br>'''Contact:''' email: alaraecedagsai99@gmail.com; +905313614710 ==Medical Education== *School of Medicine (M.D.): Istanbul Medipol University 2021- 2024 Demiroglu Bilim University 2018-2021 ==Pages authored/Co-authored/Collaborated== ===2023=== ====Authored:==== *Reni Syndrome ==Work Experience== *Wikidoc - Associate Editor-In-Chief, 2023 - Current *Yeditepe University Hospitals Cardiac Electrophysiology Lab, Ista...")
- 15:23, 25 April 2024 Alen Antony talk contribs created page Daprodustat (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=daprodustat |aOrAn=a |drugClass=reversible inhibitor of HIF-PH1, PH2 and PH3. |indicationType=treatment |indication=anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. |hasBlackBoxWarning=Yes |adverseReactions=Hypertension, Abdominal pain, Dizzines, Hypersensitivity, and thrombotic vascular events like Myocardial infarction, stroke, pulmonary embolism,...")
- 23:04, 24 April 2024 Kosar Doraghi talk contribs created page File:IMG 1177.jpeg
- 23:04, 24 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1177.jpeg
- 22:59, 24 April 2024 Kosar Doraghi talk contribs created page File:IMG 1176.jpeg
- 22:59, 24 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1176.jpeg
- 21:21, 24 April 2024 Alara E. Dagsali talk contribs created page Template:AlaraE.Dagsali (Created page with " Alara Ece Dagsali, M.D.[mailto:alaraecedagsali99@gmail.com]")
- 21:14, 24 April 2024 Alara E. Dagsali talk contribs created page Tranexamic (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Tranexamic |aOrAn=a |drugClass=hemophilia drug |indicationType=prevention |indication=Tranexamic acid injection is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. |adverseReactions=Thromboembolic Risk Seizures Hypersensitivity Reactions Visual Disturbances Dizzines...")
- 21:06, 24 April 2024 Alen Antony talk contribs created page Bexagliflozin (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=bexagliflozin }}")
- 15:32, 23 April 2024 User account Malaika Hassan talk contribs was created by Alberto Castro Molina talk contribs
- 18:44, 22 April 2024 Alara E. Dagsali talk contribs created page File:D2f97c72-bbfb-426e-b742-6e25234ba1ff 2.jpg
- 18:44, 22 April 2024 Alara E. Dagsali talk contribs uploaded File:D2f97c72-bbfb-426e-b742-6e25234ba1ff 2.jpg
- 18:43, 22 April 2024 Alara E. Dagsali talk contribs created page File:Ae8d4ea7-c895-403b-a435-56dc4996a3b0.JPG
- 18:43, 22 April 2024 Alara E. Dagsali talk contribs uploaded File:Ae8d4ea7-c895-403b-a435-56dc4996a3b0.JPG
- 03:48, 21 April 2024 Kosar Doraghi talk contribs created page File:IMG 1052.jpeg
- 03:48, 21 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1052.jpeg
- 03:47, 21 April 2024 Kosar Doraghi talk contribs created page BRENZAVVY- bexagliflozin (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=BRENZAVVY- bexagliflozin |aOrAn=a |drugClass=sodium-glucose co-transporter 2 (SGLT2) inhibitor |indicationType=treatment |indication=glycemic control in adults with type 2 diabetes mellitus |hasBlackBoxWarning=Yes |adverseReactions=female genital mycotic infections, urinary tract infection and increased urination |blackBoxWarningTitle=Warnings |blackBoxWarningBody=*Not re...")
- 03:43, 21 April 2024 Kosar Doraghi talk contribs created page File:IMG 1050.jpeg
- 03:43, 21 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1050.jpeg
- 03:40, 21 April 2024 Kosar Doraghi talk contribs created page File:IMG 1051.jpeg
- 03:40, 21 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1051.jpeg
- 03:34, 21 April 2024 Kosar Doraghi talk contribs created page File:IMG 1049.jpeg
- 03:34, 21 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1049.jpeg
- 16:05, 20 April 2024 Imam Ali Shah talk contribs created page Template:IAS (Created page with "Associate Editor-In-Chief: Imam Ali Shah, MBBS; Chandka Medical College, Larkana Pakistan")
- 16:30, 19 April 2024 Kosar Doraghi talk contribs created page Sparsentan (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi[mailto:k.doraghi@yahoo.com] |genericName=sparsentan |aOrAn=an |drugClass=endothelin and angiotensin II receptor antagonist |indicationType=treatment |indication=proteinuria(reduce) in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g |hasBlackBoxWarning=Yes |adverseReactions=Hepatotoxicity, Embryo-Fetal Tox...")
- 16:24, 19 April 2024 Kosar Doraghi talk contribs created page File:IMG 1046.jpeg
- 16:24, 19 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1046.jpeg
- 16:14, 19 April 2024 Kosar Doraghi talk contribs created page File:IMG 1045.jpeg
- 16:14, 19 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1045.jpeg
- 16:11, 19 April 2024 Kosar Doraghi talk contribs created page File:IMG 1047.jpeg